Cardiovascular complications of diabetes: role of non-coding RNAs in the crosstalk between immune and cardiovascular systems

Diabetes mellitus, a group of metabolic disorders characterized by high levels of blood glucose caused by insulin defect or impairment, is a major risk factor for cardiovascular diseases and related mortality. Patients with diabetes experience a state of chronic or intermittent hyperglycemia resulting in damage to the vasculature, leading to micro- and macro-vascular diseases. These conditions are associated with low-grade chronic inflammation and accelerated atherosclerosis. Several classes of leukocytes have been implicated in diabetic cardiovascular impairment. Although the molecular pathways through which diabetes elicits an inflammatory response have attracted significant attention, how they contribute to altering cardiovascular homeostasis is still incompletely understood. In this respect, non-coding RNAs (ncRNAs) are a still largely under-investigated class of transcripts that may play a fundamental role. This review article gathers the current knowledge on the function of ncRNAs in the crosstalk between immune and cardiovascular cells in the context of diabetic complications, highlighting the influence of biological sex in such mechanisms and exploring the potential role of ncRNAs as biomarkers and targets for treatments. The discussion closes by offering an overview of the ncRNAs involved in the increased cardiovascular risk suffered by patients with diabetes facing Sars-CoV-2 infection.

Automated summary

Diabetes mellitus, a metabolic disorder characterized by high blood glucose levels, is a major risk factor for cardiovascular diseases. Chronic or intermittent hyperglycemia in diabetes leads to vascular damage and inflammation, resulting in micro- and macro-vascular diseases. Non-coding RNAs (ncRNAs) may play a fundamental role in the interaction between immune and cardiovascular cells in diabetic complications. This review explores the function of ncRNAs as biomarkers and treatment targets, as well as their involvement in the increased cardiovascular risk in diabetic patients with Sars-CoV-2 infection.